VOCs vs FIT for Colorectal Cancer Screening
Primary Purpose
Colorectal Cancer, Colorectal Polyp
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Breath sampling
Sponsored by
About this trial
This is an interventional screening trial for Colorectal Cancer
Eligibility Criteria
Inclusion Criteria:
- Patients with and without positive FIT with a planned colonoscopy
- Patients included in the regional screening program for CRC
- Written informed consent
Exclusion Criteria:
- Pregnancy
- Inflammatory bowel disease
- Bowel prep
- Any psychiatric disease
- Previous (or still present) cancers in other organs
Sites / Locations
- Dept of Emergency and Organ transplantationRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Healthy subjects
Colorectal Cancer patients
Colonic Polyps patients
Arm Description
The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
Outcomes
Primary Outcome Measures
FIT sensitivity
Evaluate the sensitivity of fecal immunochemical test to detect Colorectal cancer patients
Breath analysis sensitivity
Evaluate the sensitivity Breath analysis to detect colorectal cancer patients
Secondary Outcome Measures
Full Information
NCT ID
NCT04407416
First Posted
May 22, 2020
Last Updated
May 27, 2020
Sponsor
Societa Italiana di Chirurgia ColoRettale
1. Study Identification
Unique Protocol Identification Number
NCT04407416
Brief Title
VOCs vs FIT for Colorectal Cancer Screening
Official Title
The Effectiveness of Breath Analysis Versus FIT for Colorectal Cancer Screening
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 2, 2020 (Actual)
Primary Completion Date
May 2, 2022 (Anticipated)
Study Completion Date
May 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Societa Italiana di Chirurgia ColoRettale
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Endogenous breath VOCs (Volatile Organic Compounds) are present in various excreted biological materials (urine, blood, faeces an breath) and their analysis offers a possibility for cancer screening. Some of these VOCs are reversed in the venous blood stream and reach the lung alveoli where some of them are exhaled.
Colorectal cancer (CRC) is one of the commonest tumours and is an important cause of cancer-related mortality. Colonoscopy is the gold standard for the diagnosis of CRC.
Screening with fecal immunochemical test (FIT) is associated with a 13-18% CRC-mortality reduction.
Aim of the study To compare the reliability of this breath analysis with Immunochemically-based Fecal Occult Blood Test.
Detailed Description
Volatile organic compounds (VOCs) are low molecular weight (<1 kDa) compounds which represent the final products of cell metabolism. Their composition can be affected by several factors including diet, hormones, environment and the presence of diseases, in particular, cancer.
Endogenous breath VOCs are present in various excreted biological materials (urine, blood, faeces an breath) and their analysis offers a possibility for cancer screening. Some of these VOCs are reversed in the venous blood stream and reach the lung alveoli where some of them are exhaled.
Colorectal cancer (CRC) is one of the commonest tumours and is an important cause of cancer-related mortality. Colonoscopy is the gold standard for the diagnosis of CRC, although its cost prevents its use for mass screening. Furthermore colonoscopy is not well accepted by patients since it is an invasive exam. Screening with fecal immunochemical test (FIT) is associated with a 13-18% CRC-mortality reduction in major randomized studies and is the most widely used non-invasive screening tool, showing fairly good specificity but a high variation in sensitivity (61-91%) and adherence to screening programmes rarely reaches 50-70% of the target population.
Recently the breath analysis has been demonstrated to be a new well accepted and non-invasive tool to detect colorectal cancer.
The purpose of this trial is to compare the reliability of this breath analysis with Immunochemically-based Fecal Occult Blood Test, which is the routinely employed tool for mass screening. A group of subjects adherent to the regional screening program for colorectal cancer prevention, who resulted positive to the FIT, will be enrolled in this study, and will have a breath sampling before undergoing colonoscopy. The predictive ability of the Breath test will be tested in a blind fashion in this selected group of high-risk subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Colorectal Polyp
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Healthy subjects
Arm Type
Active Comparator
Arm Description
The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
Arm Title
Colorectal Cancer patients
Arm Type
Active Comparator
Arm Description
The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
Arm Title
Colonic Polyps patients
Arm Type
Active Comparator
Arm Description
The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
Intervention Type
Procedure
Intervention Name(s)
Breath sampling
Intervention Description
The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
Primary Outcome Measure Information:
Title
FIT sensitivity
Description
Evaluate the sensitivity of fecal immunochemical test to detect Colorectal cancer patients
Time Frame
30 days
Title
Breath analysis sensitivity
Description
Evaluate the sensitivity Breath analysis to detect colorectal cancer patients
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with and without positive FIT with a planned colonoscopy
Patients included in the regional screening program for CRC
Written informed consent
Exclusion Criteria:
Pregnancy
Inflammatory bowel disease
Bowel prep
Any psychiatric disease
Previous (or still present) cancers in other organs
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Donato Altomare, Prof
Phone
+393397593066
Email
donatofrancesco.altomare@uniba.it
First Name & Middle Initial & Last Name or Official Title & Degree
Arcangelo Picciariello, MD
Phone
+393492185104
Email
arcangelopicciariello@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elisabetta Martinelli, MD
Organizational Affiliation
Societa Italiana di Chirurgia ColoRettale
Official's Role
Study Chair
Facility Information:
Facility Name
Dept of Emergency and Organ transplantation
City
Bari
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donato F Altomare, MD
Phone
00390805478764
Email
altomare@clichiru.uniba.it
First Name & Middle Initial & Last Name & Degree
Donato F Altomare, MD
First Name & Middle Initial & Last Name & Degree
Arcangelo Picciariello, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
30828825
Citation
Bond A, Greenwood R, Lewis S, Corfe B, Sarkar S, O'Toole P, Rooney P, Burkitt M, Hold G, Probert C. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Aliment Pharmacol Ther. 2019 Apr;49(8):1005-1012. doi: 10.1111/apt.15140. Epub 2019 Mar 3.
Results Reference
result
PubMed Identifier
23212621
Citation
Altomare DF, Di Lena M, Porcelli F, Trizio L, Travaglio E, Tutino M, Dragonieri S, Memeo V, de Gennaro G. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg. 2013 Jan;100(1):144-50. doi: 10.1002/bjs.8942.
Results Reference
result
PubMed Identifier
25386553
Citation
Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014 Oct 27;2:210. doi: 10.3389/fpubh.2014.00210. eCollection 2014.
Results Reference
result
PubMed Identifier
27493910
Citation
Mousavinezhad M, Majdzadeh R, Akbari Sari A, Delavari A, Mohtasham F. The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test. Med J Islam Repub Iran. 2016 May 9;30:366. eCollection 2016.
Results Reference
result
Learn more about this trial
VOCs vs FIT for Colorectal Cancer Screening
We'll reach out to this number within 24 hrs